Risedronate prevents bone loss in patients on hormone therapy

A new study has shown that the generically available, oral, bisphosphonate risedronate (Actonel) can prevent bone loss and related effects in patients receiving hormonal therapy for prostate cancer. … READ MORE …

Prostate cancer news reports: Wednesday, July 8, 2009

Today’s prostate cancer news reports cover items on:

  • Assessment of quality of life after radical prostatectomy
  • Permanent seed brachytherapy in treatment of localized disease
  • Cryotherapy in treatment of patients with Gleason 8-10 localized disease
  • Actonel and/or estradiol in prevention of SREs … READ MORE …